Drugs

Express Scripts provides us with the first of the big PBM drug spending trend reports.

Magellan releases its annual report on specialty drug costs.

A brief from the Kaiser Family Foundation demonstrates how Medicare's share of drug spending has grown since the introduction of Part D and expansion of Part B medication use.

A research letter in JAMA Internal Medicine discusses physicians perspectives on FDA expedited drug approval pathways.

A report from IQVIA covers expected spending and trends in global drug use over the next few years.

A study carried by the Journal of the American Medical Association reveals the absurd and despicable profits being earned by drug companies off the misery of cancer patients.

A Deloitte annual report looks at drug manufacturer returns on research and development activities.

A study from BRG confirms that hospitals are making the most of their profit opportunities in the 340B program.

The Blue Cross Blue Shield Association releases an analysis of drug price increases. Same old story.

An analysis of Medicare Part B drugs compares prices in the US with those around the world. Guess who pays way more.

An analysis in JAMA Internal Medicine suggests that the cost of drug pivotal trials may be less than what the industry suggests.